HOXB9 and neoplasm: In the tumors of the HOXB9 OE/SKOV3-injected group, however, the inhibiting effects of cisplatin on tumor progression were not significant (tumor weight, 1186.0 mg ± 473.2 mg vs. 1156.7 mg ± 401.0 mg; tumor volume, 2159.4 mm3 ± 75.4 mm3 vs. 1807.1 mm3 ± 183.3 mm3; p > 0.05 for both).